|
Genedrive PLC - Manchester-based point-of-care pharmacogenetic testing company - says its MT-RNR1 ID kit will start being used for babies requiring antibiotic treatment for infections at the Royal Hospital for Children in Glasgow. The Royal Alexandra Hospital and Princess Royal Maternity Hospital are to follow soon after, as part of a phased rollout to all NHS Scotland Health Boards with neonatal units over the coming months. The company also notes recent media coverage about MT-RNR1 ID, which reduces the risk of deafness in newborn babies. ‘We are proud that NHS Scotland has begun to implement our interventional rapid genetic test nationally, ensuring over time that it is available to neonates across Scotland who might otherwise be at risk of hearing loss,’ said Chief Executive Gino Miele. Current stock price: 1.03 pence, up 6.1% on Wednesday afternoon in London 12-month change: down 54% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
